Business Wire·May 12, 2026, 9:15 AM ET

bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026

bioAffinity Technologies reported CyPath® Lung unit sales increased nearly 300% in April 2026 compared to April 2025 based on preliminary unaudited data.
The April 2026 sales figures represent a record high for a single month & continue a first quarter 2026 trend of accelerating adoption.
The company's internal projections for unit sales growth in 2026 have been exceeded due to expanding clinical use by physicians.
CyPath® Lung is a noninvasive test utilizing flow cytometry & AI to assess lung cancer risk & manage pulmonary nodules.
The test helps detect Stage 1A lung cancer & may help avoid unnecessary invasive procedures when results are negative.
Clinical trial data for high-risk patients showed 92% sensitivity, 87% specificity, 88% accuracy, & 99% negative predictive value.
Commercial growth is driven by expanding ordering physician sites, increased peer-to-peer education, & integration into clinical workflows.
Future initiatives include a large-scale longitudinal clinical study, monitoring lung cancer survivors, & an R&D pipeline for asthma & COPD diagnostics.
The test is marketed as a Laboratory Developed Test (LDT) overseen under CLIA regulations by Precision Pathology Laboratory Services.